Products - Blood and bone marrow cancers | Topic | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Showing 226 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Product type:
Guidance
Programme:
Technology appraisal guidance
Expected publication date:
28 July 2021
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma (TA1059)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 May 2025
Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over (TA1054)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 April 2025
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia (TA1049)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 March 2025
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable (TA1048)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 March 2025
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1023)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 December 2024
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA1018)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 November 2024
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1015)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 November 2024
Avapritinib for treating advanced systemic mastocytosis (TA1012)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 November 2024
Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (TA1013)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 October 2024
Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment (TA1001)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 September 2024
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) (TA987)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 July 2024
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (TA979)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 June 2024
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) (TA978)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 May 2024
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (TA975)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 May 2024
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 May 2024
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments (TA970)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 May 2024
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (TA967)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 May 2024
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 May 2024
Published:
3 September 2018
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA968)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 April 2024
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 March 2024
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 March 2024
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 February 2024
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments (TA947)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 January 2024
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal) (TA936)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 November 2023
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal) (TA933)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 November 2023
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal) (TA932)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 November 2023
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 November 2023
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable (TA917)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 October 2023
Ruxolitinib for treating polycythaemia vera (TA921)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 October 2023
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 October 2023
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy (TA895)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 June 2023
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 June 2023
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over (TA893)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 June 2023
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA897)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 June 2023
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 May 2023
Mosunetuzumab for treating relapsed or refractory follicular lymphoma (TA892)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 May 2023
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA889)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 May 2023
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma (TA883)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 May 2023
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 March 2023
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA872)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 February 2023
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA870)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 February 2023
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA841)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 November 2022
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal) (TA842)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 November 2022
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal) (TA840)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 November 2022
Zanubrutinib for treating Waldenstrom’s macroglobulinaemia (TA833)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 October 2022
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy (TA827)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 October 2022
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal) (TA822)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 September 2022
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 August 2022
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal) (TA811)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 July 2022
Venetoclax for treating chronic lymphocytic leukaemia (TA796)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 June 2022
Ibrutinib for treating Waldenstrom’s macroglobulinaemia (TA795)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 June 2022
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 April 2022
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 April 2022
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) (TA782)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 March 2022
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal) (TA774)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 March 2022
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies (TA772)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 February 2022
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal) (TA771)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 February 2022
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA765)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 December 2021
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA726)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 September 2021
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA727)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 September 2021
Midostaurin for treating advanced systemic mastocytosis (TA728)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 September 2021
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 August 2021
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal) (TA717)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 July 2021
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) (TA714)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 July 2021
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) (TA702)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 May 2021
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) (TA703)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 May 2021
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 April 2021
Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 April 2021
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) (TA686)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 March 2021
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 March 2021
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma (TA677)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 February 2021
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 December 2020
Carfilzomib for previously treated multiple myeloma (TA657)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 November 2020
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma (TA658)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 November 2020
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 September 2020
Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) (TA646)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 September 2020
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 August 2020
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 August 2020
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 August 2020
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal) (TA634)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 June 2020
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 May 2020
Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 April 2020
Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal) (TA608)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 October 2019
Idelalisib for treating refractory follicular lymphoma (TA604)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 October 2019
Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) (TA603)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 September 2019
Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA602)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 September 2019
Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 July 2019
Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies (TA171)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
26 June 2019
Published:
18 June 2009
Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
26 June 2019
Published:
24 September 2014
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 June 2019
Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 June 2019
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 April 2019
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) (TA576)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 April 2019
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 February 2019
Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (TA552)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 December 2018
Decitabine for untreated acute myeloid leukaemia (terminated appraisal) (TA548)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 December 2018
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) (TA549)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 December 2018
Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 November 2018
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 September 2018
Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 June 2018
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 June 2018
Midostaurin for untreated acute myeloid leukaemia (TA523)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 June 2018
Obinutuzumab for untreated advanced follicular lymphoma (TA513)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 March 2018
Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 January 2018
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 October 2017
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) (TA469)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 August 2017
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 July 2017
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) (TA453)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 July 2017
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA454)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 July 2017
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) (TA452)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 July 2017
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 June 2017
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 June 2017
Elotuzumab for previously treated multiple myeloma (terminated appraisal) (TA434)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 March 2017
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) (TA437)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 March 2017
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (TA429)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 January 2017
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 January 2017
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 December 2016
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 December 2016
Pegaspargase for treating acute lymphoblastic leukaemia (TA408)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Bosutinib for previously treated chronic myeloid leukaemia (TA401)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 August 2016
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts (TA399)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 July 2016
Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 March 2016
Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 January 2016
Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
21 January 2016
Published:
22 October 2003
Bortezomib for previously untreated mantle cell lymphoma (TA370)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 December 2015
Idelalisib for treating chronic lymphocytic leukaemia (TA359)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 October 2015
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 June 2015
Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 April 2014
Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma (TA306)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 February 2014
Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) (TA270)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 December 2012
Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 January 2012
Mifamurtide for the treatment of osteosarcoma (TA235)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 October 2011
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 July 2011
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma (TA226)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 June 2011
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (TA218)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 March 2011
Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 February 2011
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal) (TA206)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 October 2010
Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) (TA207)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 October 2010
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 July 2010
Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 July 2009
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (TA137)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 February 2008
Bortezomib monotherapy for relapsed multiple myeloma (TA129)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 October 2007
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (TA119)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 February 2007
Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (TA29)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 September 2001
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
19 June 2025
Expected publication date:
5 September 2025
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
17 September 2025
Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments [ID5082]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
15 October 2025
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
15 October 2025
Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
4 July 2025
Expected publication date:
15 October 2025
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
5 November 2025
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
29 January 2026
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 February 2026
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable ID6249
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
4 March 2026
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable (MA partial review of TA663) [ID6291]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
11 March 2026
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia ID1627
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies [TSID10765]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
REGN5458 for treating relapsed or refractory multiple myeloma [TSID10443]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies [ID6491]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
3 July 2025
Expected publication date:
TBC
Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable [TSID10477]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID11949]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments [ID6413]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [TSID11991]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Subcutaneous isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [TSID11969]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia [TSID12043]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia [TSID12043]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over [TSID12036]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Resminostat for maintenance treatment of advanced mycosis fungoides or Sézary syndrome [ID6478]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor [TSID8376]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dorocubicel for treating haematological cancer when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma after 3 or more treatment lines [ID6549]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pirtobrutinib with venetoclax and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma [TSID12182]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Carfilzomib in combination for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID12176]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Elranatamab for treating relapsed or refractory multiple myeloma after treatments including anti-CD38 antibody and lenalidomide therapy [ID6591]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lisocabtagene maraleucel for treating relapsed or refractory low-grade B-cell follicular lymphoma after 1 or more treatments [ID6564]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Decitabine-cedazuridine (Inqovi) + Venetoclax for Acute myeloid leukaemia (AML) [ID12200]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID12197]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zanubrutinib for Chronic lymphocytic leukaemia (CLL) or Follicular lymphoma or Marginal zone lymphoma (MZL) or Waldenstrom's macroglobulinaemia [ID12199]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events in bone malignancies ID12150
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mosunetuzumab for treating relapsed or refractory follicular lymphoma [TSID 12081]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC